The present invention is concerned with compounds of formula ##STR00001## the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R.sup.1 is hydrogen, hydroxy, C.sub.1-6alkyl or aryl; R.sup.2 is hydrogen; optionally substituted C.sub.1-12alkyl; C.sub.3-7cycloalkyl; C.sub.2-8alkenyl, optionally substituted pyrrolidinyl or aryl; R.sup.3 is hydrogen, optionally substituted C.sub.1-6alkyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl; ##STR00002## is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 10/979,362 filed Nov. 2, 2004 now U.S. Pat. No. 7,205,312, now allowed; which is a divisional of U.S. application Ser. No. 10/238,686 filed Sep. 10, 2002, now U.S. Pat. No. 6,833,375; which is a divisional of U.S. application Ser. No. 09/624,966 filed Jul. 25, 2000, now U.S. Pat. No. 6,486,187; which is a divisional of U.S. application Ser. No. 09/214,080, filed Apr. 29, 1999, now U.S. Pat. No. 6,124,330; which is a National Stage application under 35 U.S.C. .sctn. 371 of PCT/EP97/03248 filed Jun. 19, 1997; which claims priority from EP 96.201.781.0, filed Jun. 27, 1996; the entireties of these applications are incorporated herein by reference.